Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01732588
Recruitment Status : Completed
First Posted : November 26, 2012
Results First Posted : February 13, 2015
Last Update Posted : March 6, 2015
Sponsor:
Information provided by (Responsible Party):
Medicines for Malaria Venture

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this study is to determine the bioavailability of nanoparticulate OZ439 delivered to the proximal small bowel (PSB) via the Enterion™ capsule relative to oral OZ439 suspension (current "powder in bottle" [PIB]) and oral nanoparticulate OZ439.

The study will also characterise the plasma concentration time profile of OZ439 when delivered via Enterion capsule to the PSB in comparison with OZ439 PIB formulation delivered orally and nanoparticulate OZ439 delivered orally Safety and tolerability of OZ439 formulations will be determined following delivery to the PSB and administered orally


Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: OZ439 120mg PIB Drug: 120 mg OZ439 caplet Drug: 120mg OZ439 caplet via Enterion capsule Phase 1

Detailed Description:
Previous clinical studies with OZ439 have shown variable PK and a food effect. One hypothesis is that this may be related to a 'common ion effect' leading to precipitation of the drug as a less soluble hydrochloride salt in the stomach, resulting in variable absorption of the drug. This study is designed to investigate the possibility of improving the PK profile by delivering the drug directly to the PSB, thereby bypassing the stomach. The study will compare a previously dosed PIB formulation with oral delivery of a nanoparticulate as a caplet formulation. The same caplet formulation containing nanoparticulate will be administered to the PSB via the Enterion capsule.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Three Way Randomised CrossOver Study in Healthy Subjects to Compare the Relative Bioavailability of Nanoparticulate OZ439 Delivered Via the Enterion™ Capsule to the Proximal Small Bowel With Orally Administered OZ439 as PIB Suspension and Orally Administered Nanoparticulate
Study Start Date : November 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Regimen A - 120mg OZ439 PIB
120mg single dose of OZ439 as powder in bottle (PIB) formulation
 Drug: OZ439 120mg PIB
120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
Other Name: Regimen A
Experimental: Regimen B - 120 mg OZ439 IR caplet
120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
 Drug: 120 mg OZ439 caplet
120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
Other Name: Regimen B
Experimental: Regimen C - 120 mg OZ439 caplet via Enterion capsule
120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
 Drug: 120mg OZ439 caplet via Enterion capsule
120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
Other Name: Regimen C


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. OZ439 AUC0-∞ [ Time Frame: pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose ]
    Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)

  2. OZ439 Cmax [ Time Frame: pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose ]
    The maximum observed plasma drug concentrations (Cmax)


Secondary Outcome Measures :
  1. OZ439 Tmax [ Time Frame: pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose ]
    Time of maximum observed plasma drug concentrations (Tmax)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males, or females of non-childbearing potential ie surgically sterilised or post-menopausal
  2. Age 18 to 55 years
  3. Body mass index of 18 to 30 kg/m2 inclusive
  4. Total body weight >50 kg
  5. Healthy as determined by pre-study medical history, physical examination (including body temperature) and 12-lead ECG
  6. Must have haematology, clinical chemistry and urinalysis results at screening that are within the reference range or ncs
  7. Must agree to use an adequate method of contraception
  8. Must demonstrate their ability to swallow an empty size 000 capsule
  9. Must be willing and able to communicate and participate in the whole study
  10. Must provide written informed consent

Exclusion Criteria:

  1. Evidence or history of clinically significant oncological, pulmonary, chronic respiratory, hepatic, cardiovascular, haematological, metabolic, neurological, immunological, nephrological, endocrine or psychiatric disease, or current infection
  2. Clinically relevant abnormalities in the ECG (12 standard leads) and/or QTcF >450 ms (males) or >470 ms (females)
  3. Evidence or history of clinically significant GI disease or surgery (excluding appendectomy or cholecystectomy)
  4. Any condition that could possibly affect drug absorption, eg gastrectomy or diarrhoea
  5. History of post-antibiotic colitis
  6. History of any drug or alcohol abuse in the past 2 years prior to screening
  7. Subjects who have a breath carbon monoxide reading of greater than 10 ppm at screening. Subjects who are tobacco users (including smokers and users of snuff, chewing tobacco and other nicotine or nicotine-containing products) must have stopped use within 90 days before screening
  8. Receipt of an investigational drug or participation in another clinical research study within the previous 3 months
  9. Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  10. Subjects who have previously been enrolled in this study
  11. Use of any prescription or non-prescription medications, vitamins, herbal supplements or dietary supplements within 14 days prior to the first dose
  12. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab)or human immunodeficiency virus (HIV-1 or HIV-2 antibody) results
  13. Positive urine drug screen result
  14. History of intolerance or hypersensitivity to artemisinins
  15. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
  16. Presence or history of allergy requiring treatment; hayfever is allowed unless it is active
  17. Donation or loss of >400 mL of blood within the previous 3 months
  18. Haemoglobin result below the lower limit of the reference range
  19. Regular alcohol consumption in males >21 units per week and females >14 units per week
  20. Subjects who do not have suitable veins
  21. Acute diarrhoea or constipation in the 7 days before the predicted first study day.
  22. Presence of non-removable metal objects in the abdomen
  23. Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years
  24. Failure to satisfy the investigator of fitness to participate for any other reason
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01732588


Locations
Layout table for location information
United Kingdom
Quotient Clinical
Nottingham, United Kingdom, NG11 6JS
Sponsors and Collaborators
Medicines for Malaria Venture
Investigators
Layout table for investigator information
Study Director: Fiona Macintyre, PhD Medicines for Malaria Venture
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Medicines for Malaria Venture
ClinicalTrials.gov Identifier: NCT01732588    
Other Study ID Numbers: MMV_OZ439_12_003
First Posted: November 26, 2012    Key Record Dates
Results First Posted: February 13, 2015
Last Update Posted: March 6, 2015
Last Verified: February 2015
Keywords provided by Medicines for Malaria Venture:
Bioavailability
Additional relevant MeSH terms:
Layout table for MeSH terms
Artefenomel
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents